Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Sponsor
Alexion Pharmaceuticals, Inc.
Study ID
NCT07596784
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Generalized Myasthenia Gravis
  • gMG

Eligibility Criteria

Sex
ALL
Age
18 Years - 130 Years
Healthy Volunteers
Not accepted

Interventions

  • Ravulizumab — DRUG
    Participants will receive ravulizumab via intravenous (IV) infusion.

Study Details

The primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).

Key Dates

First listed
May 19, 2026
Start date
Jul 30, 2026
Status verified
Jun 2026
Primary completion
Aug 27, 2027
Completion
Aug 27, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ravulizumab
    Participants will receive ravulizumab for up to 26 weeks.

Primary Outcome Measure

Change From Baseline in Myasthenia Gravis Activities of Daily Living Profile (MG-ADL) Total Score at Week 26 [ Time Frame: Baseline, Week 26 ]

Central Contacts

Related Studies